Menu Menu


GSK Financials       Clear


GSK        0001131399    
Filing Date Form Type Description Document
2026-03-20 6-K TRANSACTION IN OWN SHARES View Document
2026-03-19 6-K LYNAVOY (LINERIXIBAT) APPROVED BY US FDA View Document
2026-03-19 6-K TRANSACTION IN OWN SHARES View Document
2026-03-18 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-03-18 6-K TRANSACTION IN OWN SHARES View Document
2026-03-17 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-03-17 6-K TRANSACTION IN OWN SHARES View Document
2026-03-16 6-K TRANSACTION IN OWN SHARES View Document
2026-03-13 6-K US FDA APPROVES AREXVY FOR ADULTS 18-49 AIR View Document
2026-03-13 6-K TRANSACTION IN OWN SHARES View Document
2026-03-12 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-03-12 6-K TRANSACTION IN OWN SHARES View Document
2026-03-11 6-K TRANSACTION IN OWN SHARES View Document
2026-03-10 6-K TRANSACTION IN OWN SHARES View Document
2026-03-09 6-K BOARD COMMITTEE CHANGE View Document
2026-03-09 6-K GSK AND ALFASIGMA AGREE GLOBAL LINERIXIBAT RIGHTS View Document
2026-03-09 6-K TRANSACTION IN OWN SHARES View Document
2026-03-06 6-K FILING OF GSK PLC 2025 ANNUAL REPORT ON FORM 20-F View Document
2026-03-06 IRANNOTICE IRANNOTICE View Document
2026-03-06 20-F 20-F View Document
2026-03-06 6-K TRANSACTION IN OWN SHARES View Document
2026-03-05 6-K GSK PUBLISHES ANNUAL REPORT 2025 View Document
2026-03-05 6-K TRANSACTION IN OWN SHARES View Document
2026-03-04 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-03-04 6-K TRANSACTION IN OWN SHARES View Document
2026-03-03 6-K GSK COMPLETES ACQUISITION OF RAPT THERAPEUTICS View Document
2026-03-03 6-K TRANSACTION IN OWN SHARES View Document
2026-03-03 SC TO-T/A SC TO-T/A View Document
2026-03-02 6-K TRANSACTION IN OWN SHARES View Document
2026-03-02 6-K TOTAL VOTING RIGHTS View Document
2026-02-27 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-02-27 6-K TRANSACTION IN OWN SHARES View Document
2026-02-26 6-K LINERIXIBAT ACCEPTED FOR PRIORITY REVIEW IN CHINA View Document
2026-02-26 6-K BEPIROVIRSEN ACCEPTED FOR JAPAN REGULATORY REVIEW View Document
2026-02-26 6-K TRANSACTION IN OWN SHARES View Document
2026-02-25 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-02-25 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-02-25 6-K GSK ENTERS AGREEMENT TO ACQUIRE 35PHARMA View Document
2026-02-25 6-K TRANSACTION IN OWN SHARES View Document
2026-02-24 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-02-24 6-K TRANSACTION IN OWN SHARES View Document
2026-02-24 SC TO-T/A SC TO-T/A View Document
2026-02-23 6-K TRANSACTION IN OWN SHARES View Document
2026-02-20 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-02-20 6-K TRANSACTION IN OWN SHARES View Document
2026-02-19 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-02-19 6-K TRANSACTION IN OWN SHARES View Document
2026-02-18 6-K TRANSACTION IN OWN SHARES View Document
2026-02-17 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-02-17 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-02-17 6-K GSK - FOURTH TRANCHE OF SHARE BUYBACK PROGRAMME View Document
2026-02-17 6-K EXDENSUR APPROVED BY THE EUROPEAN COMMISSION View Document
2026-02-17 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-02-17 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-02-17 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-02-12 13F-HR View Document
2026-02-11 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-02-11 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-02-11 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-02-11 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-02-10 6-K CHINA CDE ACCEPTS AREXVY ADULTS 60+ APPLICATION View Document
2026-02-09 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-02-06 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-02-06 6-K NUCALA COPD APPROVED BY THE EUROPEAN COMMISSION View Document
2026-02-05 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-02-04 6-K FINAL RESULTS View Document
2026-02-02 6-K TOTAL VOTING RIGHTS View Document
2026-02-02 SC TO-T SC TO-T View Document
2026-01-26 6-K EUROPEAN COMMISSION APPROVES AREXVY FOR ADULTS 18+ View Document
2026-01-20 SC TO-C SC TO-C View Document
2026-01-20 SC TO-C SC TO-C View Document
2026-01-20 6-K GSK TO ACQUIRE RAPT THERAPEUTICS View Document
2026-01-20 6-K AGREEMENT ON CHANGES TO VIIV MINORITY SHAREHOLDING View Document
2026-01-16 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-01-15 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-01-13 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-01-07 6-K EC APPROVAL OF SHINGRIX PFS View Document
2026-01-07 6-K POSITIVE PHASE 3 DATA FOR GSK'S BEPIROVIRSEN View Document
2026-01-06 6-K EXDENSUR APPROVED IN JAPAN View Document
2026-01-05 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-01-05 6-K TOTAL VOTING RIGHTS View Document
2026-01-05 6-K NUCALA FOR ADULTS WITH COPD APPROVED IN CHINA View Document
2025-12-23 6-K GSK TO LOWER DRUG PRICES AND EXPAND ACCESS IN US View Document
2025-12-22 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-12-22 6-K TRANSACTION IN OWN SHARES View Document
2025-12-19 6-K TRANSACTION IN OWN SHARES View Document
2025-12-18 6-K TRANSACTION IN OWN SHARES View Document
2025-12-17 6-K EXDENSUR (DEPEMOKIMAB ULLA) APPROVED BY US FDA View Document
2025-12-17 6-K TRANSACTION IN OWN SHARES View Document
2025-12-16 6-K EXDENSUR (DEPEMOKIMAB) UK MHRA APPROVAL View Document
2025-12-16 6-K TRANSACTION IN OWN SHARES View Document
2025-12-15 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP View Document
2025-12-15 6-K TRANSACTION IN OWN SHARES View Document
2025-12-12 6-K DEPEMOKIMAB RECEIVES POSITIVE CHMP OPINION View Document
2025-12-12 6-K NUCALA RECEIVES POSITIVE CHMP OPINION FOR COPD View Document
2025-12-12 6-K POSITIVE CHMP OPINION ON AREXVY FOR ALL ADULTS 18+ View Document
2025-12-12 6-K TRANSACTION IN OWN SHARES View Document
2025-12-11 6-K BLUJEPA APPROVED IN US FOR GONORRHOEA INDICATION View Document
2025-12-11 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-12-11 6-K BLOCK LISTING APPLICATION View Document

Find registration statements, periodic reports, and other forms by typing ticker symbol of a company.

Ticker:

Search company filings and access detailed reports including 10-K, 10-Q, 8-K, and other critical filings. Stay informed on corporate disclosures, regulatory filings, and updates with our easy-to-use EDGAR API filings search tool.



We can also help with your taxes.

Formal Tax

www.formal.tax





(402) 804-8293


Formal Financial App
Google Play - Apple Store

created using: Admin Canvas